Tsylana’s Post

The right to health is a basic human right 🏥 On #WorldHealthDay, Amolyt Pharma, with backing from Sofinnova Partners, offers hope to patients worldwide suffering from rare endocrine and related diseases. 💫 €212m raised from VCs 💫 Expansion to 50 employees 💫 $1.05bn acquisition agreement with AstraZeneca With support from investors: Intermediate Capital Group (ICG), Tekla Capital Management, CTI Life Sciences Fund, Andera Partners, Novo Ventures, Kurma Partners, EQT Life Sciences, @Innobio 2 (Bpifrance Investissement), Sectoral Asset Management, Pontifax Venture Capital, OrbiMed, Mass General Brigham Ventures, ATEM, Crédit Agricole Création and Relyens Innovation Santé / Turenne Groupe. Read the full story, and take a look at how investment supports Europe’s most innovative healthcare and life sciences businesses ➡️ https://lnkd.in/emQzXubz #PrivateEquity #VentureCapital #SuccessStories #BuildingBetterBusinesses #pharma #healthcare

France: Case Study - Amolyt Pharma, a portfolio company of Sofinnova Partners sold to AstraZeneca for $1.05bn. Amolyt Pharma represents a major European VC success story – a French company created and incubated by a pioneering entrepreneur, backed by top European investors, including Sofinnova Partners, who led the company’s €130M series C in 2023, with participation from Intermediate Capital Group (ICG) Tekla Capital Investment LLC, CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital. READ the Invest Europe case study here https://lnkd.in/emQzXubz READ the Investors in Healthcare article here https://lnkd.in/ex8GPi53 #lifesciences #venturecapital #healthcare Antoine Papiernik Nicholas Moore Julian Hudson

I posted yesterday about how competitive the acquisition market is in biotech currently and the funding space is no different. I read a FierceBiotech article a few weeks ago about how there's been a significant decline in outside funding into the industry. However, sector-specific VC backing is on the rise with lots of biotech-focused venture companies being born. Below are the top 10 Biopharma fund raises this year - some staggering amounts of money coming into the industry. Patient Square Capital OrbiMed Lux Capital Canaan Forbion Gilde Healthcare Revelation Partners SR One Capital Management #biotech #pharma #venturecapital

TPG has closed a $580 million life sciences fund for drug development startups, medical device makers and tech-enabled healthcare services companies. The fund has already backed multiple biotechs, including antibody-drug conjugates maker MBrace Therapeutics, immunology startup Santa Ana Bio, TYK2 drug developer Sudo Biosciences and oncology-focused Bicara Therapeutics, among others. Leading the fund’s investment team are partners Carolyn Ng, Shinichiro Fuse and Lucian Iancovici MD. TPG's Life Sciences Innovation unveiling on Tuesday follows a $650 million fund at Goldman Sachs, a $500 million-plus fund at JP Morgan and about two dozen funds from biotech and life sciences specialists so far this year. More in Endpoints News: #tpg #lifesciences #biotechinvesting #biotech

BGPartner advises Novo Holdings, EQT, OrbiMed and SR One on $100 mio Series C financing of Asceneuron SA Swiss biotech company Asceneuron SA successfully closed a $100 mio oversubscribed Series C financing round. The financing round was led by Novo Holdings with new investment from EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One Capital Management, alongside participation from existing investors Merck Serono S.p.A., Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease. BGPartner advised lead investor Novo Holdings as well as the investors EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, on all Swiss legal matters and the negotiations of this Series C financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate). More information can be found here: https://lnkd.in/d278vevG More information about our legal and negotiation expertise can be found here: https://lnkd.in/eFQjD5fw #Financing #swiss #Biotech #law #negotiation #Alzheimer

Shedding the "dirty word" connotation: I wrote about the appetite for biotech crossover rounds this morning for Endpoints News, just as two of the drug development industry's largest private financings of 2024 were announced (Alumis' $259 million and Sionna's $182 million). #crossover #biotech #drugdevelopment #lifesciencesindustry #biotechindustry #pharma #venturecapital #publicmarkets #ipo

venBio Closes $528 Million Life Sciences Fund V Learn more & get our take 👇 https://lnkd.in/ghUkQKsh “With a highly concentrated portfolio and active involvement in each company, we are proud to have helped build companies that have achieved nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data.” — Dr. Aaron Royston, M.D., Managing Partner at venBio “Our portfolio is directly impacting patient lives, and we could not have achieved this without the ongoing commitment from our limited partners. Fund V is structured to enable us to continue our proven approach of being highly selective in company building, while doubling down on winners around key inflection points, including in crossover rounds and at IPO.” — Dr. Corey Goodman, Managing Partner at venBio “In structuring Fund V, our primary goal was to maintain consistency in our strategy, core team and investment discipline, and we look forward to her continued contributions to the firm.” — Dr. Richard Gaster, M.D., Ph.D., Managing Partner at venBio #funding #lifesciences #SoHCNews

PitchBook recently released the top most active PE Biotech & Life Science investors list over the past five years. Here is the list below 👇 📝 KKR invested over $500 billion with 14 investments including, Bushu Pharmaceuticals Ltd. for around $750 million. 🖊 Thompson Street Capital Partners came in 2nd with 13 investments totaling $4.5 billion . Their average deal was over $50 million including Vector Laboratories, Inc.. 🧪 Boston based, Ampersand Capital Partners spent over $3 billion across 9 different investments. 👨🔬 French based, ARCHIMED staked over $8.5 billion invested with 9 deals across Biopharma, IVD & Life Science Tools. 👩🔬BroadOak Capital Partners targets early growth companies across Life Sciences and invested in Sanguine Biosciences this year. Over 8 deals, they have invested $0.3 billion. 💹 Other listed investors included GTCR LLC ($35 billion), Arsenal Capital Partners ($11.1 billion), DevCo Partners ($0.7 billion), NovaQuest Capital Management ($1.8 billion), Merieux Equity Partners ($1.6 billion) & OrbiMed ($17 billion). Interesting to learn who invests where and the article from PitchBook is listed in the comments below. Let me know your thoughts too! #scirec #investment #lifescience #biotech #diagnostics

A crucial path towards meeting revenue goals and seeing marketable results is attracting the right investors, especially in the life science industry. Strong management, successful strategic plans, and key experience in the field have a common dividend: they're vital deciding factors for biotech investors. Interested in learning more? We've got that covered. Read the inside scoop with Bracken's Managing Partner Jim Gilligan here: https://lnkd.in/eHs8Kaxj #Biopharma #Investing #DueDiligence #Bracken

January 2, 2024: 2024 will be a landmark year for Cosmos Pharmaceuticals LLC with its revolutionary medication adherence platform introduction to the early adopters! The year kicks off with Cosmos' much-anticipated device, FortisKap, landing in the hands of patients in our study groups. This platform promises to revolutionize medication adherence offering real time dosing timeframes, dosing quantities and predictive risk management. Cosmos will showcase its innovation at the upcoming RESI JPM conference in San Francisco next week and connect with key investors and potential partners. "Most Investable StartUp" recognition: Life Science Nation’s recognition validates Cosmos' potential and supports the company's $1.25M seed capital raise. This funding supports commercialization development and entry into the market. #RESIJPM #RESIJPM24 #RESISANFRAN